Samus Therapeutics, Inc.
🇺🇸United States
Clinical Trials
8
Active:0
Completed:0
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:4
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (50.0%)Phase 2
3 (37.5%)Early Phase 1
1 (12.5%)A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Samus Therapeutics, Inc.
- Registration Number
- NCT05612633
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Phase 1
Terminated
- Conditions
- Recurrent Glioblastoma Multiforme (GBM)Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype AstrocytomaGrade 3 or 4 AstrocytomaGlioblastoma Surgery
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04782609
- Locations
- 🇺🇸
University of California, Las Angeles Medical Center, Los Angeles, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Registration Number
- NCT04505358
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- Radiation: Tau Positron emission tomography (PET)Radiation: Fluorodeoxyglucose (FDG) Positron emission tomography (PET)Diagnostic Test: Cerebrospinal fluid (CSF) BiomarkersDiagnostic Test: Blood BiomarkersBehavioral: Rating ScalesDrug: Placebo
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04311515
- Locations
- 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
🇺🇸JEM Research, Lake Worth, Florida, United States
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03935568
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found